Results 51 to 60 of about 35,942 (184)

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

Advanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li, Yumei Wang, Xiaoxi Fan, Miao Xu, Jiawen Li, Wenfei Tan, Jianxiang Zhang, Heran Li   +7 more
wiley   +1 more source

Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity.

PLoS ONE, 2019
Systemic lupus erythematous (SLE) is a chronic multi-organ autoimmune disease. Genetic and environmental factors contribute to disease onset and severity.
Samar M Hammad, Jasmyn R Hardin, Dulaney A Wilson, Waleed O Twal, Paul J Nietert, James C Oates   +5 more
doaj   +1 more source

Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2*

Journal of Lipid Research, 2009
Sphingosine 1-phosphate (S1P), a bioactive lipid mediator, stimulates proliferation and contractility in hepatic stellate cells, the principal matrix-producing cells in the liver, and inhibits proliferation via S1P receptor 2 (S1P2) in hepatocytes in ...
Hitoshi Ikeda, Naoko Watanabe, Isao Ishii, Tatsuo Shimosawa, Yukio Kume, Tomoaki Tomiya, Yukiko Inoue, Takako Nishikawa, Natsuko Ohtomo, Yasushi Tanoue, Satoko Iitsuka, Ryoto Fujita, Masao Omata, Jerold Chun, Yutaka Yatomi   +14 more
doaj   +1 more source

Integrating Spatial Proteogenomics in Cancer Research

Advanced Science, EarlyView.
Xx xx. ABSTRACT Background: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment.
Yida Wang, Yang Wu, Feng Zhang, Parthiban Periasamy, Haiyue You, Denise Goh, Rachel Elizabeth Ann Fincham, Xin Ning, Danping Wu, Lu Liu, Ying Jiang, Zhiwen Qian, Joe Yeong, Yan Zhang   +13 more
wiley   +1 more source

Endothelial Functions of Sphingosine-1-phosphate

Cellular Physiology and Biochemistry, 2010
The biologically active sphingolipid sphingosine-1-phosphate (S1P) plays key functions in the immune, inflammatory, and cardiovascular systems. In the vasculature, S1P and its receptors are involved in vessel morphogenesis and angiogenesis during embryonic development and in the adult organism both under normal and pathological conditions.
Lucke, Susann, Levkau, Bodo
openaire   +2 more sources

Sphingosine‐1‐phosphate: dual messenger functions

FEBS Letters, 2002
The sphingolipid metabolite sphingosine‐1‐phosphate (S1P) is a serum‐borne lipid that regulates many vital cellular processes. S1P is the ligand of a family of five specific G protein‐coupled receptors that are differentially expressed in different tissues and regulate diverse cellular actions. Much less is known of the intracellular actions of S1P. It
Payne, Shawn G, Milstien, Sheldon, Spiegel, Sarah   +2 more
openaire   +2 more sources

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Does Siponimod Exert Direct Effects in the Central Nervous System?

Cells, 2020
The modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes in lymph nodes.
Markus Kipp
doaj   +1 more source

Clinical assessment of mocravimod as a victim of drug–drug interactions via CYP3A4 metabolism and transporters

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Mocravimod, a novel immunomodulator targeting sphingosine‐1‐phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested that cytochrome (CYP) 3A4 is the primary enzyme involved in mocravimod metabolism.
Dymphy R. Huntjens, Stephan Oehen, Elisabeth Kueenburg   +2 more
wiley   +1 more source

Sphingosine‐1‐phosphate stimulates cortisol secretion

FEBS Letters, 2003
We show here for the first time that sphingosine‐1‐phosphate (Sph‐1‐P) stimulates cortisol secretion in zona fasciculata cells of bovine adrenal glands. This effect was dependent upon protein kinase C (PKC) and extracellular Ca2+, and was inhibited by pertussis toxin. Sph‐1‐P activated phospholipase D (PLD) through a pertussis toxin‐sensitive mechanism,
Rábano, Miriam, Peña, Ana, Brizuela, Leyre, Marino, Aida, Macarulla, José Marı́a, Trueba, Miguel, Gómez-Muñoz, Antonio   +6 more
openaire   +2 more sources